Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
KIT exon 11 mutation + KIT exon 17 mutation
Cancer:
Gastrointestinal Stromal Tumor
Drug:
sunitinib
(
c-KIT inhibitor
,
VEGFR inhibitor
,
PDGFR inhibitor
) +
IPI 493
(
HSP90 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Clin Cancer Res
Title:
The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations
Excerpt:
The combination of IPI-493 with SUN remarkably enhances antitumor effects in GIST, especially in tumors carrying double KIT mutations.
DOI:
10.1158/1078-0432.CCR-11-0562
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login